Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

Therapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.

BMJ Mental Health, published by the esteemed BMJ PUBLISHING GROUP, is a pioneering open-access journal dedicated to advancing research and knowledge in the field of Psychiatry and Mental Health. Launched in 2023, this journal has rapidly established itself within the academic community, achieving a prestigious Q1 ranking and a ranking of #123 out of 567 in its category, placing it in the 78th percentile according to Scopus. With its base in the United Kingdom, the journal aims to foster impactful research through its commitment to accessibility, allowing professionals, researchers, and students alike to engage with high-quality content freely. The E-ISSN: 2755-9734 enables seamless digital access to cutting-edge studies, reviews, and perspectives that address the complexities of mental health, thereby paving the way for better practices and innovations in mental health care. Join a community of dedicated scholars and practitioners in reshaping the landscape of mental health research with BMJ Mental Health.

World Psychiatry is a leading peer-reviewed journal dedicated to advancing the field of psychiatry and mental health. Published by WILEY and located in the United States, this esteemed journal boasts an impressive impact factor, ranking Q1 in the Psychiatry and Mental Health category for 2023. Recognized for its scholarly contributions, World Psychiatry ranks #1 out of 567 in the Scopus database for medicine in psychiatry and mental health, placing it in the top 1% of its field. The journal covers a wide scope of research topics, aiming to facilitate dialogue and innovation among researchers, professionals, and students alike. Though it does not offer open access, its comprehensive articles and analyses are accessible to a broad audience engaged in mental health studies. With converged years from 2007 to 2024, the journal continues to serve as a critical resource for the latest advancements and evidence-based practices in psychiatry.

Current Psychiatry Research and Reviews is an innovative open access journal dedicated to the dynamic field of psychiatry and mental health. Published by Bentham Science Publishers Ltd, this journal provides a platform for researchers and practitioners to disseminate pivotal findings, reviews, and advancements in psychiatric research. While the journal currently holds a Q4 status in the Psychiatry and Mental Health category, it seeks to elevate standards with interdisciplinary contributions aimed at improving patient outcomes and treatment methodologies. With a publication window spanning from 2019 to 2024, the journal aims to enhance global discussions in mental health sciences, encouraging submissions that explore evidence-based practices, innovative therapeutic techniques, and the epidemiology of mental health disorders. The journal's address in the Netherlands positions it strategically within Europe’s vibrant research community, making it an essential resource for researchers, professionals, and students alike who are invested in the evolution of psychiatric science.

Current Psychiatry Reports, published by Springer, is a premier academic journal dedicated to the dissemination of cutting-edge research in the field of psychiatry and mental health. With a significant impact factor reflecting its esteemed position at Q1 in Psychiatry, this journal ranks an impressive #35 out of 567 in its category, placing it within the 93rd percentile of psychiatric publications as per Scopus metrics. Since its inception in 1996, it has provided a vital platform for clinicians, researchers, and students to explore and discuss contemporary psychiatric issues, advancements, and methodologies. While Current Psychiatry Reports is a subscription-based journal, its robust scholarly contributions are invaluable for practitioners and scholars looking to stay abreast of developments and empirical studies that shape the field. Based in the United States, at ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY 10004, it remains an authoritative source for evidence-based insights that guide both research and clinical practice in mental health.

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

Child and Adolescent Psychiatry and Mental Health, published by BMC, is a premier open access journal dedicated to advancing the field of mental health and psychiatric care for children and adolescents. Since its inception in 2007, the journal has fostered a global dialogue among researchers, clinicians, and policy makers by disseminating high-quality research that addresses critical issues in child and adolescent psychiatry. With an impressive Q1 ranking in Pediatrics, Perinatology and Child Health and Psychiatry and Mental Health, it holds a significant position within the academic community, ranking 28th out of 330 in its field. This standing enhances its visibility and relevance, appealing to a wide range of professionals interested in evidence-based practices. As an open access journal, it ensures that research is freely accessible to those who need it most, facilitating greater collaboration and progress. The journal is committed to publishing diverse articles that span various aspects of mental health, including preventive measures, therapeutic interventions, and the intersection of mental health with social determinants. Researchers, practitioners, and students alike will find valuable insights and innovations within its pages, making it an indispensable resource in the field.

Welcome to the Journal of Pediatric Psychology, a prestigious publication that has been at the forefront of advancing our understanding of psychological development in children since its inception in 1976. Published by Oxford University Press Inc., this journal serves as a vital platform for research in both Developmental and Educational Psychology and Pediatrics, Perinatology, and Child Health, boasting an impressive Q1 ranking in both categories as of 2023. With its ISSN 0146-8693 and E-ISSN 1465-735X, this journal is dedicated to disseminating innovative research findings, clinical practices, and theoretical advancements that shape the field of pediatric psychology. Although the journal does not currently offer Open Access options, it remains highly respected in the academic community, holding a significant position in Scopus rankings. Our commitment is to foster an insight-driven dialogue among researchers, professionals, and students to better understand the psychological well-being of children. Join us in exploring the important intersection of pediatric health and psychological science.